» Articles » PMID: 37480145

Long Non-coding RNA CCHE1 Modulates LDHA-mediated Glycolysis and Confers Chemoresistance to Melanoma Cells

Overview
Journal Cancer Metab
Publisher Biomed Central
Specialty Oncology
Date 2023 Jul 21
PMID 37480145
Authors
Affiliations
Soon will be listed here.
Abstract

Melanoma is considered as the most common metastatic skin cancer with increasing incidence and high mortality globally. The vital roles of long non-coding RNAs (lncRNAs) in the tumorigenesis of melanoma are elucidated by emerging evidence. The lncRNA cervical carcinoma high-expressed 1 (CCHE1) was overexpressed and acted as an oncogene in a variety of cancers, while the function of CCHE1 in melanoma remains unclear. Here, we found that CCHE1 was highly expressed in melanoma and correlated with the poorer survival of melanoma patients. Depletion of CCHE1 inhibited the proliferation, induced cell apoptosis and suppressed in vivo tumor growth. To further understand the functional mechanism of CCHE1, the interacting partners of CCHE1 were identified via RNA pull-down assay followed by mass spectrometry. CCHE1 was found to bind lactate dehydrogenase A (LDHA) and acted as a scaffold to enhance the interaction of LDHA with the fibroblast growth factor receptor type 1 (FGFR1), which consequently enhanced LDHA phosphorylation and activity of LDHA. Inhibiting CCHE1 strikingly suppressed the glycolytic flux of melanoma cells and lactate generation in vivo. Further study demonstrated that CCHE1 desensitized melanoma cells to dacarbazine and inhibition of glycolysis reversed CCHE1-induced chemoresistance. These results uncovered the novel function of CCHE1 in melanoma by reprogramming the glucose metabolism via orchestrating the activity of LDHA.

Citing Articles

Glucose Metabolism and Tumor Microenvironment: Mechanistic Insights and Therapeutic Implications.

Andryszkiewicz W, Gasiorowska J, Kubler M, Kublinska K, Palkiewicz A, Wiatkowski A Int J Mol Sci. 2025; 26(5).

PMID: 40076506 PMC: 11900028. DOI: 10.3390/ijms26051879.


m6A- and m5C- modified lncRNAs orchestrate the prognosis in cutaneous melanoma and m6A- modified LINC00893 regulates cutaneous melanoma cell metastasis.

Shi H, Tian C, Wu M, Ma L, Sun J, Chen H Skin Res Technol. 2024; 30(7):e13842.

PMID: 38965799 PMC: 11224130. DOI: 10.1111/srt.13842.


Identification of novel disulfidptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of skin cutaneous melanoma patients.

Cheng S, Wang X, Yang S, Liang J, Song C, Zhu Q Skin Res Technol. 2024; 30(7):e13814.

PMID: 38924611 PMC: 11197043. DOI: 10.1111/srt.13814.


Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.

Wang S, Wu X, Wu X, Cheng J, Chen Q, Qi Z BMC Cancer. 2024; 24(1):156.

PMID: 38291366 PMC: 10829303. DOI: 10.1186/s12885-024-11920-8.

References
1.
Grammatikakis I, Lal A . Significance of lncRNA abundance to function. Mamm Genome. 2021; 33(2):271-280. DOI: 10.1007/s00335-021-09901-4. View

2.
Chen Y, Wang C, Sun X, Wang C, Liu T, Wang D . Long non-coding RNA CCHE1 overexpression predicts a poor prognosis for cervical cancer. Eur Rev Med Pharmacol Sci. 2017; 21(3):479-483. View

3.
Xerri L, Battyani Z, Grob J, Parc P, Hassoun J, Bonerandi J . Expression of FGF1 and FGFR1 in human melanoma tissues. Melanoma Res. 1996; 6(3):223-30. DOI: 10.1097/00008390-199606000-00005. View

4.
Ooi A, Gomperts B . Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA. Clin Cancer Res. 2015; 21(11):2440-4. PMC: 4452440. DOI: 10.1158/1078-0432.CCR-14-1209. View

5.
Zawacka-Pankau J, Grinkevich V, Hunten S, Nikulenkov F, Gluch A, Li H . Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem. 2011; 286(48):41600-41615. PMC: 3308870. DOI: 10.1074/jbc.M111.240812. View